Press Release: Dr. Kwatra receives IND from the FDA to study osimertinib (AZD9291) in EGFRvIII-positive glioblastoma


Dr. Madan Kwatra, Director of the Glioblastoma Drug Discovery Group at Duke, is pleased to announce that the FDA has approved the group’s IND entitled: “Phase II evaluation of osimertinib in newly diagnosed glioblastoma patients expressing EGFRvIII.” Dr. Kwatra is planning to conduct a randomized, multi-center trial to test the efficacy of osimertinib in EGFRvIII-positive GBM patients. A key feature of the trial will be a comprehensive characterization of each patient’s tumor as well as the establishment of PDX and stem cell models from each patient’s tumor.

Leave a Reply

Your email address will not be published. Required fields are marked *